1. Scrip
  2. >>Focus On Asia
  3. >>China

GSK CEO Andrew Witty Under Fire About China During Q2 Call

 
• By Tamra Sami

GSK tried to highlight sales during its Q2 earnings call, but analysts and media grilled the CEO on GSK’s China bribery allegations, which Witty did not expand upon except to say that some execs acted outside of the company’s “processes and controls.”

GlaxoSmithKline PLC CEO Andrew Witty was fairly mum about the company’s alleged bribery charges in China during the company’s earnings call July 24. The CEO held a call with media to discuss China specifically, ahead of the company’s normal call, presumably to fend off China questions in advance.

Not surprisingly, journalists and analysts grilled him throughout both events, with some asking if the turn of events called into...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

Battle For Obesity Market Shifts Gears in India: Will Wegovy Trump Mounjaro?

 
• By Anju Ghangurde

Novo Nordisk debuts Wegovy in India, gears for pole position in obesity. The Danish group’s leadership doesn’t appear too perturbed about the head start for Lilly’s Mounjaro or the imminent arrival of generic semaglutide next year.

Bitcoin Player Parataxis To Acquire Bridge Biotherapeutics After IPF Failure

 
• By Jung Won Shin

After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.

Chinese Developers Showcase Potentially Differentiated Weight Loss Assets At ADA

 
• By Xu Hu

Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.